Constellation Pharmaceuticals (CNST) Prices 6.5M Share Common Offering at $34.50/Sh

Pre-Open Movers 12/10: (ASNA) (GNW) (SFIX) Higher; (CONN) (SCYX) (FRAN) Lower (more...)

Today's Pre-Open Movers

Ascena Retail Group (NASDAQ: ASNA) 27% HIGHER; reported Q1 EPS of $0.18, versus ($0.09) reported last year. Revenue for the quarter came in at $1.3 million, versus $1.34 million reported last year.

Conn's (NASDAQ: CONN) 26% LOWER; reported Q3 EPS of $0.61, $0.07 better than the analyst estimate of $0.54. Revenue for the quarter came in at $377.71 million versus the consensus estimate of $394.29 million.

SCYNEXIS, Inc. (NASDAQ : SCYX) 22.3% LOWER; commenced an... More

After-Hours Movers 12/09: (ASNA) (SFIX) (MDB) Higher; (SCYX) (LVGO) (REGN) Lower (more...)

Today's After-Hours Movers

Ascena Retail Group (NASDAQ: ASNA) 27% HIGHER; reported Q1 EPS of $0.18, versus ($0.09) reported last year. Revenue for the quarter came in at $1.3 million, versus $1.34 million reported last year.

SCYNEXIS, Inc. (NASDAQ : SCYX) 18.6% LOWER; commenced an underwritten public offering of shares of its common stock and warrants. In addition, SCYNEXIS expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock and warrants being offered on the same... More

Constellation Pharmaceuticals (CNST) PT Raised to $55 at Oppenheimer

Oppenheimer analyst Silvan Tuerkcan raised the price target on Constellation Pharmaceuticals (NASDAQ: CNST) to $55.00 (from $40.00) while maintaining a Outperform rating.

The analyst comments "CNST updated CPI-0610 data with efficacy stable in the key first-line (1L) population (n=15) and excellent tolerability in all settings. SVR35... More

Constellation Pharmaceuticals (CNST) Announces Proposed Public Offering of Common Stock

Constellation Pharmaceuticals, Inc., (Nasdaq: CNST) a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that it has commenced an underwritten public offering of 4.75 million shares of its common stock. All of the shares are being offered by... More

Constellation Pharmaceuticals (CNST) PT Raised to $65 at Baird

Baird analyst Michael E. Ulz raised the price target on Constellation Pharmaceuticals (NASDAQ: CNST) to $65.00 (from $35.00) while maintaining a Outperform rating.

Constellation Pharmaceuticals (CNST) Halted on LUDP

Constellation Pharmaceuticals (NASDAQ: CNST) Halted on LUDP

Constellation Pharmaceuticals (CNST) Provides Updated Preliminary Data from MANIFEST Clinical Trial with CPI-0610 in Oral and Poster Presentations at ASH

Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today provided an update of preliminary data from the MANIFEST clinical trial in oral and poster presentations at the annual meeting of the American Society of Hematology (ASH) in Orlando.

MANIFEST is an open-label Phase 2 clinical trial of the Companys bromodomain and extra-terminal domain (BET) protein inhibitor CPI-0610 in patients with myelofibrosis (MF). Arm 3 is evaluating CPI-0610 in combination with ruxolitinib in JAK-inhibitor-naïve MF patients. Arms 1 and 2 are studying CPI-0610 as a monotherapy or in combination with ruxolitinib in... More